Premium
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
Author(s) -
Staerk L.,
Gerds T. A.,
Lip G. Y. H.,
Ozenne B.,
Bonde A. N.,
Lamberts M.,
Fosbøl E. L.,
TorpPedersen C.,
Gislason G. H.,
Olesen J. B.
Publication year - 2018
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/joim.12683
Subject(s) - medicine , rivaroxaban , apixaban , dabigatran , atrial fibrillation , stroke (engine) , anesthesia , cohort , warfarin , mechanical engineering , engineering
Background Comparative data of non‐vitamin K antagonist oral anticoagulants ( NOAC ) are lacking in patients with atrial fibrillation ( AF ). Objective We compared effectiveness and safety of standard and reduced dose NOAC in AF patients. Methods Using Danish nationwide registries, we included all oral anticoagulant‐naïve AF patients who initiated NOAC treatment (2012–2016). Outcome‐specific and mortality‐specific multiple Cox regressions were combined to compute average treatment effects as 1‐year standardized differences in stroke and bleeding risks (g‐formula). Results Amongst 31 522 AF patients, the distribution of NOAC /dose was as follows: dabigatran standard dose (22.4%), dabigatran‐reduced dose (14.0%), rivaroxaban standard dose (21.8%), rivaroxaban reduced dose (6.7%), apixaban standard dose (22.9%), and apixaban reduced dose (12.2%). The 1‐year standardized absolute risks of stroke/thromboembolism were 1.73–1.98% and 2.51–2.78% with standard and reduced NOAC dose, respectively, without statistically significant differences between NOAC s for given dose level. Comparing standard doses, the 1‐year standardized absolute risk (95% CI ) for major bleeding was for rivaroxaban 2.78% (2.42–3.17%); corresponding absolute risk differences (95% CI) were for dabigatran −0.93% (−1.45% to −0.38%) and apixaban, −0.54% (−0.99% to −0.05%). The results for major bleeding were similar for reduced NOAC dose. The 1‐year standardized absolute risk (95% CI ) for intracranial bleeding was for standard dose dabigatran 0.19% (0.22–0.50%); corresponding absolute risk differences (95% CI) were for rivaroxaban 0.23% (0.06–0.41%) and apixaban, 0.18% (0.01–0.34%). Conclusions Standard and reduced dose NOAC s, respectively, showed no significant risk difference for associated stroke/thromboembolism. Rivaroxaban was associated with higher bleeding risk compared with dabigatran and apixaban and dabigatran was associated with lower intracranial bleeding risk compared with rivaroxaban and apixaban.